Phenotypic analysis and effects of sequential administration of activated canine lymphocytes on healthy beagles

被引:19
作者
Hoshino, Yuki [1 ]
Takagi, Satoshi [1 ]
Osaki, Tomohiro [2 ]
Okumura, Masahiro [1 ]
Fujinaga, Toru [1 ]
机构
[1] Hokkaido Univ, Lab Vet Surg, Dept Vet Clin Sci, Grad Sch Vet Med, Sapporo, Hokkaido 0600818, Japan
[2] Hokkaido Univ, Grad Sch Vet Med, Vet Teaching Hosp, Sapporo, Hokkaido 0600818, Japan
关键词
activated lymphocytes; canine; cytokine; tumor immunotherapy;
D O I
10.1292/jvms.70.581
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
We attempted to accumulate the basic data for evaluation of activated lymphocyte therapy for small animal medicine. The peripheral blood mononuclear cells (PBMCs) collected from healthy dogs were activated using anti-CD3 antibody and human recombinant (hr) interleukin (lL)-2 and reactivated using hr interferon (IFN)-alpha and hr IL-2. The property of obtained cells was compared with PBMCs. The number of cells was shown to have increased approximately > 50-fold by cultivation. The proportion of CD8(+) cells was significantly increased, the cytotoxicity of the cultured cells was revealed to have been reinforced. Additionally, CD56 mRNA levels tended to have increased. The cells obtained by this method were confirmed to be activated lymphocytes. Furthermore, we investigated the effects of sequential administration of the obtained cells to healthy dogs. By sequential administration of the activated lymphocytes, the cell proliferative activity, proportion of CD4(+) cells and CD8(+) cells, and serum IFN-gamma concentration were shown to have increased, and no severe adverse effects were observed. Consequently, activated lymphocytes could be induced using anti-CD3 antibody and IL2 in healthy dogs, and sequential administration of activated lymphocytes reinforced the recipient's immunity.
引用
收藏
页码:581 / 588
页数:8
相关论文
共 42 条
[1]   Mouse CD1-specific NK1 T cells: Development, specificity, and function [J].
Bendelac, A ;
Rivera, MN ;
Park, SH ;
Roark, JH .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :535-562
[2]   Anticancer Vaccines [J].
Bergman, Philip J. .
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2007, 37 (06) :1111-+
[3]  
Blackwood L, 1996, J AM VET MED ASSOC, V209, P98
[4]   Characterization of cDNA and the genomic sequence encoding canine neural-cell adhesion molecule, CD56/N-CAM [J].
Bonkobara, M ;
Sato, T ;
Takahashi, N ;
Kasahara, Y ;
Yagihara, H ;
Tamura, K ;
Isotani, M ;
Azakami, D ;
Ono, K ;
Washizu, T .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2005, 107 (1-2) :171-176
[5]  
Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7
[6]   CD8+ T-cell selection, function, and death in the primary immune response in vivo [J].
Callan, MFC ;
Fazou, C ;
Yang, HB ;
Rostron, T ;
Poon, K ;
Hatton, C ;
McMichael, AJ .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (10) :1251-1261
[7]   INTERFERON - A CYTOTOXIC LYMPHOCYTE-T DIFFERENTIATION SIGNAL [J].
CHEN, LK ;
TOURVIEILLE, B ;
BURNS, GF ;
BACH, FH ;
MATHIEUMAHUL, D ;
SASPORTES, M ;
BENSUSSAN, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (07) :767-770
[8]   Cause of death in dogs according to breed: A necropsy survey of five breeds [J].
Craig, LE .
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 2001, 37 (05) :438-443
[9]   Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels [J].
Ebina, T ;
Ogama, N ;
Shimanuki, H ;
Kubota, T ;
Isono, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (09) :555-560
[10]   The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients [J].
Ebina, T ;
Fujimiya, Y ;
Yamaguchi, T ;
Ogama, N ;
Sasaki, H ;
Isono, N ;
Suzuki, Y ;
Katakura, R ;
Tanaka, K ;
Nagata, K ;
Takano, S ;
Tamura, K ;
Uno, K ;
Kishida, T .
BIOTHERAPY, 1998, 11 (04) :241-253